The effect of short-term glycemic regulation with gliclazide and metform in on postprandial lipemia

Experimental and Clinical Endocrinology and Diabetes

Volumn 113, Issue 2, 2005, Pages 80-84

  Emral, R ^a   Koseoglulari O ^a   Tonyukuk, V ^a   Uysal, A R ^a   Kamel, N ^a   Corapcioglu D ^a  

^a ANKARA UNIVERSITY   (Turkey)

Author keywords

Diabetes mellitus; Postprandial lipidemia

Indexed keywords

C PEPTIDE; GLICLAZIDE; HIGH DENSITY LIPOPROTEIN; INSULIN; LOW DENSITY LIPOPROTEIN; METFORMIN; TRIACYLGLYCEROL;

ARTICLE; CHEMICAL ANALYSIS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; DIET RESTRICTION; FEMALE; HUMAN; HYPERLIPIDEMIA; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; REGULATORY MECHANISM; RISK FACTOR; STATISTICAL ANALYSIS;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; FASTING; GLICLAZIDE; HOMEOSTASIS; HUMANS; HYPOGLYCEMIC AGENTS; LEPTIN; METFORMIN; POSTPRANDIAL PERIOD;

EID: 15244349836     PISSN: 09477349     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-830536     Document Type: Article

References (29)

1. Attia N, Durlach V, Roche D, Paul JL, Soni T, Zahouani A, Landron F, Labrousse F, Leutenegger M, Girard-Globa A. Post-prandial metabolism of triglyceride-rich lipoproteins in non-insulin-dependent diabetic patients before and after bezafibrate treatment. Eur J Clin Invest 1997; 27: 55-63
2. Bierman EL. Atherogenesis in diabetes. Aterioscler Thromb 1992; 12: 647-656
3. Ceriello A, Taboga C, Tonutti L, Quagliaro L, Piconi L, Bais B, Da Ros R, Motz E. Evidence for an independent and cumulative effect of post-prandial hypertriglyceridemia and hyperglycemia on endothelial dysfunction and oxidative stress generation: effect of short- and long-term simvastatin treatment. Circulation 2002; 106: 1211-1218
4. Chen Y-DI, Reaven GM. Intestinally derived lipoproteins: metabolism and clinical significance. Diabetes Metab Rev 1991; 7: 191-208
5. DECODE Study Group. Consequences of the new diagnostic criteria for diabetes in older men and women (Diabetes Epidemiology: Collaborative Analysis of Diagnostic Criteria in Europe). Diabetes Care 1999; 22: 1667-1671
6. Donahue RP, Orchard TJ. Diabetes mellitus and macrovascular complications: An epidemiological perspective. Diabetes Care 1992; 15: 1141-1155
7. Durlach V. Postprandial lipemia in diabetes. How? Why? Diabetes Metab 1995; 21: 112-117
8. Evans M, Anderson RA, Graham J, Ellis GR, Morris K, Davies S, Jackson SK, Lewis MJ, Frenneaux MP, Rees A. Clofibrate therapy improves endothelial function and reduces postprandial lipemia and oxidative stress in type 2 diabetes mellitus. Circulation 2000; 101: 1773-1779
9. European Diabetes Epidemiology Group. Comment in Lancet: Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. Diabetes epidemiology: Collaborative analysis of diagnostic criteria in Europe. Lancet 1999; 354: 617-621
10. Friedewald WT, Levy RI, Fredericson S. Estimation of the concentration of low lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502
11. Fontbonne A, Eschwege E, Cambien F, Richard JL, Ducimetiere P, Thibult N, Warnet JM, Claude JR, Rosselin GE. Hypertriglyceridaemia as a risk factor of coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes. Diabetologia 1989; 32: 300-304
12. Jeppesen J, Hollenbeck CB, Zhou M-Y. Relation between insulin resistance, hyperinsulinemia, postheparin plasma lipoprotein lipase activity and postprandial lipemia. Atherioscler Thromb Vasc Biol 1995; 15: 320-324
13. Jeppesen J, Zhou MY, Reaven GM. Effect of metformin on postprandial lipemia in patients with fairly to poorly controlled NIDDM. Diabetes Care 1994; 17: 1093-1099
14. Kumar N, Dey CS. Gliclazide increases insulin receptor tyrosine phosphorylation but not p38 phosphorylation in insulin-resistant skeletal muscle cells. J Exp Biol 2002; 205: 3739-3746
15. Lewis GF, Carpentier A, Adeli K, Giacca A. Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocr Rev 2002; 23: 201-229
16. Maehata E, Yano M, Shiba T, Yamakado M, Inoue M, Suzuki S. Insulin resistance index (HOMA-R method). Nippon Rinsho 2002; 8: 341-350
17. Mero N, Malmstrom R, Steiner G, Taskinen MR, Syvanne M. Postprandial metabolism of apolipoprotein B-48 and B-100 containing particles in type 2 diabetes mellitus:Relations to angiographically verified severity of coronary artery disease. Atherosclerosis 2000; 150: 167-177
18. Mero N, Syvanne M, Taskinen MR. Postprandial lipid metabolism in diabetes. Atherosclerosis 1998; 141: 53-55
19. Parks EJ. Recent findings in the study of postprandial lipemia. Curr Atheroscler Rep 2001; 3: 462-470
20. 2. Relationship of the plasma levels of this lipoprotein species to its composition, to the magnitude of postprandial lipemia, and to the activities of lipoprotein lipase and hepatic lipase. J Clin Invest 1987; 80: 341-347
21. Reaven GM. Multiple CHD risk factors in type 2 diabetes: beyond hyperglycaemia. Diabetes Obes Metab 2002; 1: 13-18
22. Ruotolo G. Howard BV. Dyslipidemia of the metabolic syndrome. Curr Cardiol Rep 2002; 4: 494-500
23. Schernthaner G. Improvement of insulin action is an important part of the antidiabetic effect of metformin. Horm Metab Res Suppl 1985; 15: 116-120
24. Skrapari I, Perea D, Ioannidis I, Karabina SA, Elisaf M, Tselepis AD, Karagiannacos P, Katsilambros N. Glibenclamide improves postprandial hypertriglyceridaemia in type 2 diabetic patients by reducing chylomicrons but not the very low-density lipoprotein subfraction levels. Diabet Med 2001; 18: 781-785
25. Taskinen MR. Hyperlipidemia in diabetes. Ballieres Clin Endocrinol Metab 1990; 4: 743-775
26. Vaverkova H. Dyslipoproteinemia and diabetes mellitus. Vnitr Lek 2000; 46: 532-538
27. Weintraub MS, Eisenberg S, Breslow JL. Different patterns of post-prandial lipoprotein metabolism in normal, type IIa, type III, and type IV hyperlipoproteinemic individuals. Effects of treatment with cholestyramine and gemfibrozil. J Clin Invest 1987; 79: 1110-1119
28. West KM, Ahuja MM, Bennett PH, Czyzyk A, De Acosta OM, Fuller JH, Grab B, Grabauskas V, Jarrett RJ, Kosaka K, Keen H, Krolewski AS, Miki E, Schliak V, Teuscher A, Watkins PJ, Strober JA. The role of circulating glucose and triglycéride concentrations and their interactions with other "risk factors" as determinants of arterial disease in nine diabetic population samples from the WHO multinational study. Diabetes Care 1983; 6: 361-369
29. Yoshino G, Hirano T, Kazumi T. Dyslipidemia in diabetes mellitus. Diabetes Res Clin Pract 1996; 33: 1-14